MedTrace Logo

Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes

NCT00932048 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-09-06

No results posted yet for this study

Summary

Type 2 diabetes mellitus significantly increases the risk for the development of atherosclerosis. Recently, atherosclerosis imaging with 18F-FDG PET (18F-Fluorodeoxyglucose Positron Emission Tomography) is useful for tracking inflammation within plaque and monitoring the response to drug therapy

The purpose of this study is to determine whether FDG-PET is capable of detecting atherosclerotic vascular inflammation and monitoring the early effects of statins in type 2 diabetic patients. The usefulness of FDG-PET in risk stratification is also investigated.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin 10mg once daily for 12 weeks

Sponsors & Collaborators

  • Korea University

    lead OTHER

Principal Investigators

  • Kyung Mook Choi, MD. PhD · Korea University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-01-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00932048 on ClinicalTrials.gov